Apramycin (also known as Ai3-29795; Nebramycin II) is a broad spectrum and aminoglycoside class of antibiotic, which binds to the deep groove of the RNA. Apramycin consumption at farm level is most probably driving the increasing occurrence of apramycin/gentamicin cross-resistant [aac(3)-IV positive] E. coli in diseased pigs and healthy finishers at slaughter. Apramycin inhibits A. pleuropneumoniae FMV 87-682 with MIC50 of 8 mg/L. Apramycin (1/4 MIC) in the medium decreases the rate of growth of the bacterial strains tested, and causes the postantibiotic effect (PAE) up to 5 hours.
Physicochemical Properties
Molecular Formula | C21H43N5O15S |
Molecular Weight | 637.66 |
Exact Mass | 637.247 |
Elemental Analysis | C, 39.56; H, 6.80; N, 10.98; O, 37.64; S, 5.03 |
CAS # | 65710-07-8 |
Related CAS # | 65710-07-8 (sulfate);37321-09-8; |
PubChem CID | 3081544 |
Appearance | White to yellow solid powder |
Density | 1.56 |
Boiling Point | 949.8ºC at 760 mmHg |
Melting Point | >168ºC (dec.) |
Flash Point | 528.2ºC |
LogP | 3.825 |
Hydrogen Bond Donor Count | 13 |
Hydrogen Bond Acceptor Count | 20 |
Rotatable Bond Count | 6 |
Heavy Atom Count | 42 |
Complexity | 841 |
Defined Atom Stereocenter Count | 17 |
SMILES | S(=O)(=O)(O[H])O[H].O1[C@@]([H])([C@@]([H])(C([H])([H])[C@@]2([H])[C@@]1([H])[C@@]([H])([C@@]([H])([C@@]([H])(O[C@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)N([H])[H])O[H])O[H])O2)N([H])C([H])([H])[H])O[H])N([H])[H])O[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])(C([H])([H])[C@]1([H])N([H])[H])N([H])[H])O[H])O[H] |
InChi Key | WGLYHYWDYPSNPF-RQFIXDHTSA-N |
InChi Code | InChI=1S/C21H41N5O11.H2O4S/c1-26-11-14(30)18-8(33-20(11)37-21-16(32)13(29)10(25)9(4-27)34-21)3-7(24)19(36-18)35-17-6(23)2-5(22)12(28)15(17)31;1-5(2,3)4/h5-21,26-32H,2-4,22-25H2,1H3;(H2,1,2,3,4)/t5-,6+,7-,8+,9-,10-,11+,12+,13+,14-,15-,16-,17-,18+,19+,20-,21-;/m1./s1 |
Chemical Name | (2R,3R,4S,5S,6S)-2-[[(2R,3S,4R,4aR,6S,7R,8aS)-7-amino-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl]oxy-4-hydroxy-3-(methylamino)-2,3,4,4a,6,7,8,8a-octahydropyrano[3,2-b]pyran-2-yl]oxy]-5-amino-6-(hydroxymethyl)oxane-3,4-diol sulfuric acid |
Synonyms | Apramycin (sulfate); Apramycin sulphate; Apramycin Sulfate; Apramycin-Sulfate; ApramycinSulfate |
HS Tariff Code | 2934.99.03.00 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
Targets | Aminoglycoside | ||
ln Vitro | Apramycin consumption at farm level is most probably driving the increasing occurrence of apramycin/gentamicin cross-resistant [aac(3)-IV positive] E. coli in diseased pigs and healthy finishers at slaughter. Apramycin inhibits A. pleuropneumoniae FMV 87-682 with MIC50 of 8 mg/L. Apramycin (1/4 MIC) in the medium decreases the rate of growth of the bacterial strains tested, and causes the postantibiotic effect (PAE) up to 5 hours. Apramycin significantly reduces the haemolytic activity of A. pleuropneumoniae and affects the capsular material production of this isolate and of one isolate of P. multocida (type A). Apramycin induces translation errors, as assayed by incorporation of leucine, isoleucine and serine, although this effect occurs only to a limited extent, in cell-free systems from Escherichia coli programmed with poly(U). Apramycin inhibits the translocation step of protein synthesis both in vivo, in protoplasts of Bacillus megaterium, and in vitro, in cell-free systems from E. coli. | ||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
[1]. J Antimicrob Chemother.2006 Jul;58(1):101-7. [2]. Int J Antimicrob Agents.1999 Aug;12(3):229-37. [3]. Immunopharmacol Immunotoxicol.1992;14(1-2):191-205. |
||
Additional Infomation | Apramycin sulfate is a glycoside and an amino cyclitol. |
Solubility Data
Solubility (In Vitro) | Water : 100~200 mg/mL(313.65 mM) |
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (156.82 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication. Solubility in Formulation 2: PBS : 100 mg/mL (156.82 mM)  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.5682 mL | 7.8412 mL | 15.6823 mL | |
5 mM | 0.3136 mL | 1.5682 mL | 3.1365 mL | |
10 mM | 0.1568 mL | 0.7841 mL | 1.5682 mL |